الوصف

Safety profiles of phytocannabinoids in epilepsy patients are reviewed, including hepatotoxicity risk with concurrent valproate use. Somnolence and decreased appetite are common adverse effects.

Figure 29

Chart

Source Paper

Receptors and Channels Possibly Mediating the Effects of Phytocannabinoids on Seizures and Epilepsy.

Pharmaceuticals (Basel, Switzerland) (2020)

PMID: 32751761

DOI: 10.3390/ph13080174

Cite This Figure

![Figure 29: Safety profiles of phytocannabinoids in epilepsy patients are reviewed, including hepatotoxicity risk with concurrent valproate use. Somnolence and decreased appetite are common adverse effects.]()

> Source: Lara Senn et al. "Receptors and Channels Possibly Mediating the Effects of Phytocannabinoids on Se." *Pharmaceuticals (Basel, Switzerland)*, 2020. PMID: [32751761](https://pubmed.ncbi.nlm.nih.gov/32751761/)

<figure>
  <img src="" alt="Safety profiles of phytocannabinoids in epilepsy patients are reviewed, including hepatotoxicity risk with concurrent valproate use. Somnolence and decreased appetite are common adverse effects." />
  <figcaption>Figure 29. Safety profiles of phytocannabinoids in epilepsy patients are reviewed, including hepatotoxicity risk with concurrent valproate use. Somnolence and decreased appetite are common adverse effects.<br>  Source: Lara Senn et al. "Receptors and Channels Possibly Mediating the Effects of Phytocannabinoids on Se." <em>Pharmaceuticals (Basel, Switzerland)</em>, 2020. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32751761/">32751761</a></figcaption>
</figure>

أدلة ذات صلة

CBD لـ الأرق

التقييم A · 103 دراسات